[
    "{\"step_by_step_thinking\": \"Tocilizumab is not a conventional synthetic disease-modifying antirheumatic drug (csDMARD). It is a biologic disease-modifying antirheumatic drug (bDMARD) that targets the interleukin-6 (IL-6) receptor. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]